Early breast cancer planning starts from a clear standard: adjuvant whole-breast radiotherapy is built around 3D conformal treatment with appropriate compensation, especially field-in-field and mixed-energy beams when needed, to keep dose across the breast homogeneous. The chapter also states that hypofractionated whole-breast irradiation carries the strongest level of evidence.
That opening principle drives every later decision. A tumor bed boost lowers local recurrence, but low-risk patients may not need it; APBI is still not the standard of care, although it is acceptable in selected low-risk patients with unifocal disease. For the broader framework, read our complete guide to target volume delineation and field setup. If you want related site coverage on breast disease burden, see our article on the projected global rise in breast cancer by 2050.
In this article
Planning principles in early breast cancer
The chapter is direct on technique selection: standard adjuvant treatment for early breast cancer remains 3D CRT with appropriate compensation to produce a homogeneous dose through the breast tissue. In practice, that means field-in-field and, when required, mixed-energy beams are not cosmetic refinements. They are part of the standard approach described in the text.
The dose schedule is positioned just as clearly. The highest level of evidence supports hypofractionated whole-breast irradiation, which makes hypofractionation the reference pathway rather than a niche option. The chapter therefore ties geometry and fractionation together: good planning is not only about shaping fields, but also about choosing the delivery pattern with the strongest support.
Boost logic comes next. A subsequent dose to the tumor bed, meaning the lumpectomy cavity, further reduces the risk of local recurrence. At the same time, the chapter does not turn boost into a reflex. It allows omission in low-risk patients, which means the decision sits at the intersection of recurrence risk, cavity definition, and technical feasibility.
When boost is used, planning is most commonly performed with an en face electron beam. Energy selection is based on the depth to the tumor bed plus a margin, but it should not extend beyond the anterior surface of the pectoralis muscles. For a deep tumor bed, mini-tangents can be considered. That distinction matters. It prevents the common mistake of forcing electrons into a geometry that no longer suits them.
APBI is handled as a selective alternative, not a wholesale replacement for whole-breast treatment. The chapter says it is not yet the standard of care, but it is acceptable for selected low-risk patients with unifocal disease. Within that setting, both 3D CRT and IMRT may be used. The deciding factor is careful patient selection matched to precise target definition.
Imaging, surgery, and pathology before radiotherapy
Before contouring starts, the chapter insists on a strong diagnostic foundation. Thorough physical examination, adequate pre-operative imaging, and pathological review are presented as direct inputs to diagnosis, staging, and radiation planning.
Every patient should undergo mammography at diagnosis. Ultrasound is commonly added. MRI has limited indications in early-stage disease, but when images are available they should still be reviewed before planning. The reason is practical rather than theoretical: those studies help secure adequate margins for whole-breast treatment and improve target definition when the plan includes a boost or APBI.
The treatment pathway is also laid out clearly. Image-guided biopsy generally confirms the diagnosis. For ductal carcinoma in situ, surgery is lumpectomy, or segmental excision, alone. For early invasive disease, the recommendation is lumpectomy plus sentinel lymph node biopsy. That sequence matters because the eventual radiotherapy target depends on what surgery left behind and how clearly the cavity can be recognized on planning CT.
Pathology review then closes the loop with a concrete margin standard. The chapter requires no tumor on ink for invasive disease and 2 mm for pure DCIS, citing the 2016 SSO-ASTRO consensus guideline. This is not a minor note. It shapes confidence that the surgical bed has been adequately resected and frames how a boost or APBI should be approached.
The surgeon is encouraged, but not required, to place clips at surgery. When clips are present, they help define the tumor bed and improve radiographic localization before treatment delivery. The chapter specifically points out that clips can be particularly useful for APBI, where geometric precision becomes central rather than optional.
Read together, this section makes a simple point. If mammography, ultrasound, MRI when available, operative details, clips, and pathology are not reviewed as a single package, the plan loses anatomic confidence exactly where margin quality and accurate bed localization matter most.
CT simulation, positioning, and DIBH
The chapter gives straightforward CT acquisition rules. For whole-breast treatment, CT should be performed with slice thickness of 3 mm or less, either in the supine or prone position. For APBI, thinner slices of 1.5 to 2 mm through the lumpectomy cavity may improve cavity delineation.
In the supine setup, the patient is placed on a breast board with both arms above the head. For left-sided breast cancer, deep inspiration breath hold should be considered in order to reduce heart dose. The chapter links that choice directly to cardiac sparing rather than treating it as a generic technology add-on.
Prone positioning is presented more selectively. Patients with pendulous breasts may benefit from reduced separation and improved tissue homogeneity in planning, which may reduce acute toxicity. Prone positioning also reduces lung dose and may be used for heart avoidance.
Still, the text makes an important caution explicit. If the tumor bed abuts the chest wall, the heart can paradoxically move closer to the treatment field in the prone position. That warning is valuable in daily practice because it blocks a one-size-fits-all approach based only on departmental preference.
Reproducibility is another major point. In prone positioning, the patient should be placed on a dedicated prone breast board, and comfort must be protected because it directly affects day-to-day reproducibility. Patients with orthopedic injuries to the back or neck may not be ideal candidates for prone treatment.
Practical comparison between supine and prone treatment
The chapter contrasts both positions in a way that is useful when the decision revolves around homogeneity, organs at risk, and reproducibility.
| Position | Setup described in the chapter | Advantages mentioned | Cautions mentioned |
|---|---|---|---|
| Supine | Breast board with both arms above the head | DIBH may be considered for left-sided cases to reduce heart dose | No specific limitation is highlighted beyond the need for appropriate planning |
| Prone | Dedicated prone breast board with close attention to comfort for reproducibility | Reduced separation, improved tissue homogeneity, possible reduction in acute toxicity, lower lung dose, and potential heart avoidance | The heart may move closer to the field if the tumor bed abuts the chest wall; patients with back or neck orthopedic injuries may be poor candidates |
Organs at risk and cardiac contouring
For early breast cancer planning, the heart and lungs should be contoured in every case. The chapter is explicit here because dose estimation in those structures is part of the core assessment of the plan.
The heart should be contoured superiorly to the bifurcation of the pulmonary artery. That contour should include the pericardium and the epicardial fat located between the heart muscle and the pericardium, but it does not need to extend into pericardial fat outside the pericardium. Figure 11.8 makes that border visually concrete.
When cardiac avoidance is discussed, the chapter keeps the main evidentiary focus on reducing mean heart dose. At the same time, it recognizes a more detailed layer of planning: emerging data suggest importance of dose to the left anterior descending artery and the left ventricle. Those structures may also be contoured according to the atlases published by Feng et al. and Duane et al.
Operationally, this passage helps avoid two opposite errors. One is using a heart contour that is too crude to be meaningful. The other is overextending the contour into tissue the chapter specifically says does not need to be included. The balance described in the text is narrow, but it is also practical.
Target delineation in early breast cancer
Target delineation starts with two core structures when whole-breast treatment is planned: the breast tissue itself and the lumpectomy cavity. If APBI is selected, the chapter adds two derivative volumes, the lumpectomy CTV and the lumpectomy PTV.
Table 11.1 is the key geometric reference in this part of the chapter. It lays out the anatomic borders, expansions, and exclusions that directly influence field design.
Table 11.1. Suggested target volumes for 3D planning in early breast cancer
The table below summarizes how the chapter defines each volume and where each contour should stop. Those limits matter because they prevent unnecessary extension into non-target structures while preserving margin where the lumpectomy cavity demands it.
| Target volume | Definition and description |
|---|---|
| Breast | Clinical reference is required for breast tissue delineation. Breast tissue may be wired or borders may be placed clinically at the time of CT. Contour should include all glandular breast tissues. The cranial border should be below the head of the clavicle and at the insertion of the second rib. Caudal border is defined by the loss of breast tissue. Medial border is at the edge of the sternum and should not cross midline. Lateral border is defined by the midaxillary line but is dependent on ptosis of the breast tissue. Anterior border is the skin or a few millimeters from the skin surface for dose reporting, and the posterior border is the pectoralis muscles and muscles of the chest wall. The volume should not include these muscles or the ribs. Borders may extend slightly beyond these definitions to ensure adequate margin on the lumpectomy cavity, particularly in extreme medial or lateral cases. |
| Lumpectomy cavity | Seroma, surgical clips, and notable differences in the glandular breast tissue should be included. Comparison to the contralateral breast may be useful, particularly when fluid and or surgical clips are not present. All imaging studies should be reviewed prior to planning to assist in delineating this volume. This volume should not extend outside of the breast tissue. |
| Lumpectomy CTVa | Lumpectomy cavity with a 1.0 to 1.5 cm expansion. This volume should not extend outside of the body or into the pectoralis muscles and or muscles of the chest wall. |
| Lumpectomy PTVa | Lumpectomy CTV with a margin based on setup uncertainty and predicted patient motion, generally 0.5 to 1.0 cm. This volume may extend outside of the patient surface and into the pectoralis muscles and or muscles of the chest wall. Adjustments to this volume may be necessary for dose-reporting purposes. |
Source: Target Volume Delineation and Field Setup, 2nd Edition (Table 11.1)
a For APBI only; for whole-breast irradiation, the lumpectomy cavity alone is the boost target.
This table shows why whole-breast contouring cannot be reduced to an outer silhouette. The chapter demands clinical reference, recognition of glandular tissue, and respect for anatomic borders from the sternum to the midaxillary line, without pulling ribs or muscle into the target. It also leaves room for slight border extension when that is needed to maintain adequate margin around the cavity in very medial or lateral cases.
For the lumpectomy cavity, the text combines direct and indirect clues. Seroma and clips are the starting point, but changes in glandular tissue and comparison with the opposite breast can also help when the cavity is not obvious. That is why review of pre-operative imaging appears so repeatedly in the chapter: without it, the very structure that defines the boost may become uncertain.
In APBI, the geometric sequence is especially clear. First comes the cavity. Then comes a CTV expansion of 1.0 to 1.5 cm that must stay out of the body surface, pectoralis muscles, and chest wall muscles. Finally comes a PTV expansion of 0.5 to 1.0 cm according to setup uncertainty and expected motion. The chapter also notes that the reporting volume may need adjustment, which is a useful reminder that coverage geometry and reporting geometry are not always identical.
The figures sharpen this logic further. In Figure 11.3, APBI cavity definition relies on seroma, clips placed by the surgeon, and review of mammogram, ultrasound, and MRI when available. The CTV is typically a 1.5 cm expansion around the cavity that excludes pectoralis muscle, rib, and chest wall, stays inside the contoured breast tissue, and usually does not extend to the skin, remaining 5 mm from the patient surface. In that example, the PTV is formed by an expansion of approximately 5 mm around the CTV, depending on institutional setup uncertainty.
What the chapter figures show about technique, fields, and dose
The chapter figures turn principles into field geometry, beam choice, and dose examples. They show how the same clinical reasoning takes different forms in supine planning, prone planning, APBI, and focal boost treatment.
Technical summary of Figures 11.1 through 11.8
The captions allow the practical examples below to be condensed into one working view of how planning choices are implemented.
| Figure | Clinical situation | Main technical message |
|---|---|---|
| 11.1 | Supine axial images for a woman with left-sided stage I breast cancer | An anatomic example of the supine setup used for left-sided planning |
| 11.2 | Prone axial images for a woman with left-sided DCIS | An anatomic example of the prone setup in early left-sided breast disease |
| 11.3 | APBI plan | The cavity is based on seroma, clips, and review of mammogram, ultrasound, and MRI; the CTV is typically a 1.5 cm expansion that excludes pectoralis muscle, rib, and chest wall, stays inside the breast, and usually stops 5 mm from the skin; the PTV is approximately a 5 mm expansion |
| 11.4 | Supine breast plan with tangent fields | Field-in-field is used for homogeneity with a small MLC block for cardiac shielding; prescribed dose is 42.4 Gy at 2.65 Gy per fraction followed by an electron boost to 10 Gy at 2.5 Gy per fraction |
| 11.5 | Prone breast plan with tangent fields | Field-in-field is again used for homogeneity; prescribed dose is 42.4 Gy at 2.65 Gy per fraction followed by a mini-tangent photon boost to 10 Gy at 2.5 Gy per fraction, and the posterior field edge should include part of the pectoralis muscle |
| 11.6 | APBI plan | Combination of mini-tangent photon fields with an en face electron field |
| 11.7 | Tumor bed boost in the supine position | Electron energy of 12 MeV is chosen to ensure 90% isodose coverage to the anterior surface of the pectoralis muscle |
| 11.8 | Heart contour | The heart includes the pericardium but not the pericardial fat extending outside the pericardium |
Source: Target Volume Delineation and Field Setup, 2nd Edition (Figs. 11.1-11.8)
Two messages stand out across these figures. First, field-in-field is used as a core homogeneity tool in both supine and prone whole-breast plans. Second, boost technique follows cavity geometry: en face electrons when depth and surface relationship support them, mini-tangent photons when the anatomy favors that path, and mixed photon-electron approaches in APBI when the plan calls for it.
The numbers make that reasoning tangible. Both whole-breast examples, supine and prone, prescribe 42.4 Gy in 2.65 Gy fractions followed by a 10 Gy boost in 2.5 Gy fractions. The focal electron boost example uses 12 MeV to carry the 90% isodose line to the anterior surface of the pectoralis muscle. Those are not decorative details. They are the chapter’s clearest examples of how depth, target location, and heart avoidance translate into executable planning choices.
References cited in the chapter
For detailed contouring of the left anterior descending artery and the left ventricle, the chapter points to two published atlases: Feng et al. and Duane et al..
Those citations support a specific refinement of cardiac planning. Mean heart dose remains the main evidence-backed endpoint, but the chapter makes room for more anatomic assessment when a department wants to evaluate LAD and LV dose explicitly.
In the end, this early breast cancer chapter is concise without being thin. It connects standard technique, boost selection, selective APBI use, image and pathology review, treatment position, cardiac sparing, and geometric target limits in one coherent clinical sequence. For the broader context, return to the main guide on target volume delineation and field setup.
